• Overview
• Board of Directors
• Scientific Advisory Board
• Senior Management
• Drug Discovery Partnerships
• Clients & Collaborators
• Business Strategy

Drug Discovery Partnerships

PsychoGenics has established Drug Discovery partnerships with a number of Pharmaceutical and Biotech companies and several more partnerships are in advanced stages of negotiation.

Established partnerships include:

• Roche - PsychoGenics Inc., and Roche, Basel, Switzerland, have entered into a drug discovery and development agreement in which they combine their complementary strengths and expertise to identify a new generation of treatments for neuropsychiatric disorders. read more
• Dainippon Sumitomo Pharma – March 2008, PsychoGenics has entered into a drug discovery agreement with Dainippon Sumitomo Pharma, Co., Ltd., Japan, to screen selected compounds in PsychoGenics’ proprietary Drug Discovery Systems, with the aim of identifying new therapies for CNS disorders. read more
• Eli Lilly and Company – January 2008, PsychoGenics entered into an additional drug discovery agreement with Eli Lilly and Company. Per the agreement, Lilly will supply pre-candidate compounds that PsychoGenics will evaluate using its proprietary drug discovery technologies, for the treatment of neuropsychiatric disorders. read more
• Cephalon – November 2007, PsychoGenics entered into a drug discovery agreement with Cephalon. The agreement provides that Cephalon will supply compounds that are prospectively suitable for neuropsychiatric disorders to PsychoGenics for evaluation using its proprietary drug discovery technologies. read more
• Sepracor – August 2007, PsychoGenics and Sepracor entered into a drug discovery partnership to identify and develop new and novel treatments for neuropsychiatric disorders.
• Psylin Neurosciences – January 2007, PsychoGenics together with Amylin Pharmaceuticals formed a new company focused on the discovery and development of peptide hormones for the treatment of psychiatric disorders, utilizing PsychoGenics’ proprietary Drug Discovery Systems and Amylin’s proprietary polypeptide hormone library. read more
• Eli Lilly – December 2006, PsychoGenics is evaluating Lilly drug candidates using its proprietary Drug Discovery Systems for the treatment of neuropsychiatric disorders. read more
• Sosei Co Ltd – April 2006, PsychoGenics’ proprietary Drug Discovery Systems combined with Sosei’s Drug Reprofiling Platform to rapidly identify new therapies and treatments for CNS disorders. read more